# A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

> **NCT05606757** · PHASE2 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Ventral Hernia
- Abdominal Hernia

## Interventions

- **DRUG:** BOTOX Dose A
- **DRUG:** Placebo for BOTOX
- **DRUG:** BOTOX Dose B
- **DRUG:** BOTOX Dose C

## Key facts

- **NCT ID:** NCT05606757
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-07
- **Primary completion:** 2025-04-22
- **Final completion:** 2025-09-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05606757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05606757, "A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05606757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*